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Muhammad A. Siddiqui1,3* , Suhel Ashraff2, Derek Santos1 and Thomas Carline1Abstract: Life expectancy in patient with established kidney failure is considerably shortened with worsening
quality of life. Through the provision of renal replacement therapy, survival and quality of life of advanced renal
disease patients can be markedly improved. Haemodialysis and peritoneal dialysis are the treatment modalities in
patients with end-stage renal disease. The efficiency of haemodialysis treatment relies on the functional status of
vascular access. Vascular access and its related problems represent the main factors that determine a rise in the rate
of incidence of the disease among haemodialysis patients and, consequently, a rise in the healthcare expenses.
Arteriovenous fistula is the most efficient method, as it has a low risk of infection and mortality, and can ensure
long-term functional access. However, maturation of an arteriovenous fistula is a complex process and is not well
understood; significant numbers of arteriovenous fistula fail to develop sufficiently prior to their use for haemodialysis
due to either lack of vessel maturation or spontaneous thrombosis. There are multiple blood markers and human
factors that contribute to the maturation of fistula. Endothelial function is one of the most important determinants of
arteriovenous fistula maturation. Early fistula failure is usually due to thrombosis which can be triggered by haematoma,
by low flow rates resulting from low blood pressure, or by a hypercoagulable state. Impairment of endothelial function
is associated with decreased arterial remodelling and final venous lumen diameter. Arteriovenous fistula anastomoses
need early proliferation of endothelial cells to restore the barrier, permeability, and biochemical monitoring roles of
endothelial cells in managing vascular repair, local thrombosis, neointimal hyperplasia, and inflammation. The purpose
of this review was to discuss the maturation of AVF and endothelial dysfunction.
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Endothelial dysfunctionBackground
Chronic kidney disease (CKD) is a critical condition with
considerable public health implications. The global mean
(95%CI) CKD prevalence in five stages was 13.4% (11.7–
15.1%) and stages 3–5 was 10.6% (9.2–12.2%) [1]. In 2014,
the number of adult patients starting renal replacement
therapy (RRT) in the UK was 7411 equating to an incidence
rate of 115 pmp, compared with 109 pmp in 2013 [2]. There
are a number of factors, which have to be taken into ac-
count when deciding the usage of RRT in patients suffering
from advanced renal disease, such as evaluation of electro-
lyte and acid-base balance, intravascular volume, uraemia,* Correspondence: drasadi@hotmail.com
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(http://creativecommons.org/publicdomain/zedietary needs, haemodynamic status, urine output, and the
pathology of the disease in each individual case. The benefits
of RRT have to be compared with the possible hazards of
surgical intervention, such as bleeding caused by anticoagu-
lants, as well as all types of complications that accompany
the central venous access. Many patients with chronic
kidney disease are still unknown, because the serum creatin-
ine fails to identify decreasing kidney function, especially in
women and old individuals [3, 4]. According to the Quality
and Outcomes Framework, the diagnosis of chronic kidney
disease and improvement of treatments will be mediated by
the introduction of estimated glomerular filtration rate
(eGFR) reporting, as well as by the preservation of patient
records required of all the UK general practitioners [5].
Dialysis and transplantation provide alternative ways
of taking over the work of advanced renal disease pa-
tients. The most efficient form of therapy for advancedle is distributed under the terms of the Creative Commons Attribution 4.0
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haemodialysis is the next best option. The efficiency of
haemodialysis treatment relies on a functional status of
vascular access (VA). According to the National Institute
for Health and Clinical Excellence Guidelines [6], VA
and its related problems represent the main factors that
determine a rise in the rate of incidence of the disease
among haemodialysis patients and, consequently, a rise
in the healthcare expenses. To ensure that the dialysis
therapy can be efficiently undertaken, all patients need a
fully developed fistula that is appropriate for the process
of cannulation. Arteriovenous fistula (AVF) is the most
efficient method, as it has a low risk of infection and
mortality, and can ensure long-term functional access
[7, 8]. Unfortunately, significant numbers of AVF fail to
develop sufficiently prior to their use for haemodialysis
due to either lack of vessel maturation or spontaneous
thrombosis [9].
It is likely that one of the most important determi-
nants of AVF maturation is the ability of the inflow
artery and the outflow vein to respond to the increased
blood flow that occurs upon anastomosis of the artery
and vein [10]. AVF maturation is the ability of the inflow
artery and the outflow vein to respond to the increased
blood flow that occurs upon anastomosis of the artery
and vein. A healthy response to the anastomosis is an
increase in blood flow and corresponding increase in
shear stress [11] which stimulates the endothelial cells to
release nitric oxide (NO) and other vasodilatory sub-
stances [12]. The main purpose of this review was to dis-
cuss the maturation of AVF and endothelial dysfunction
in an advance kidney disease.
Haemodialysis
Progressive and permanent renal failure is most fre-
quently treated with haemodialysis. RRT with haemo-
dialysis does not provide true replacement of renal
function. However, by removing waste solutes and excess
body water and restoring biochemical and acid-base
balance, haemodialysis has considerably improved the
morbidity and mortality of end-stage renal disease (ESRD)
patients. A suitable type of vascular access has to be
created to establish a connection between the circulation
system of the patient and the haemodialysis cycle, in order
to provide haemodialysis in ESRD patients.
Vascular access problems represent the main deter-
minant of morbidity among haemodialysis patients and
put a considerable degree of financial pressure on the
healthcare sector [13, 14]. Successful haemodialysis
depends on the provision of safe, efficient, and durable
vascular access. Establishing and maintaining effective
vascular access is a demanding process for both patients
and renal services. These demands are set to increase in
response to an RRT population that is becomingincreasingly dependent on haemodialysis, whilst also in-
creasing in population size, age, and co-morbidity.
Vascular access can be divided into three categories:
arteriovenous fistula, central venous catheter (CVC) and
arteriovenous graft (AVG).
Of these, CVCs are used temporarily to provide vascu-
lar access for haemodialysis whilst the patient awaits cre-
ation or maturation of an AVF or AVG or because no
suitable options for permanent vascular access are avail-
able [15]. AVF is considered to provide the best long-
term functional vascular access, with a reduced risk of
thrombosis or infection, and is the most cost-effective
[16]. There are logistical hurdles to this late presentation
to renal services, fitness for surgery, suitable peripheral
vascular anatomy, delays due to primary or secondary
access failure, and slow rates of AVF maturation.
Konner et al. [17] had also obtained a high success rate
(70–90%) of native AVF construction in their study on a
randomized sample of ESRD patients. Despite the fact
that it is not without its problems, the arteriovenous fis-
tula offers better quality access for dialysis as it has a
long-lasting primary patency rate, avoids the need for
other numerous procedures, and has the most reduced
rates of morbidity and mortality among all types of vas-
cular access [18].
Endothelial function
The endothelium is the largest organ in the body con-
sisting of endothelial cells lining every blood vessel.
Adults possess enough endothelial cells that cover a sur-
face area of approximately 1 to 7 m2, with a total weight
of around 1 kg and a total quantity of 1013–6078 indi-
vidual cells [19]. In healthy subjects, vascular endothe-
lium has many functions: it can identify hormonal
stimuli (vasoactive substances) as well as mechanical
stimuli (pressure and shear stress). Endothelial cells
regulate inflammation, cell proliferation, coagulation,
and vascular tone due to their output of a number of
compounded substances [20]. Endothelium produced
vasodilatory materials such as C-type natriuretic peptide,
various endothelium-derived hyperpolarising elements,
prostacyclin, and NO, whereas vasoconstrictor materials
are reactive oxygen species, thromboxane A2, angioten-
sin II, and endothelin-1 [21]. In addition, there are a
number of inflammatory regulators, such as nuclear
factor-kB, vascular cell adhesion molecule-1, E-selectin,
NO, and intercellular adhesion molecule-1 which play
an integral part of endothelial function.
Gresele et al. reported that fibrinogen, prostacyclin,
thromboxane A2, plasminogen activator inhibitor-1, NO,
tissue factor inhibitor, von Willebrand factor, and plas-
minogen activator act as modulators for haemostasis
[22]. Permeability, inflammation, coagulation, cell adhe-
siveness, and vascular tone are among the variety of
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In medium to large arteries, healthy endothelial cells
contribute to the prevention of atherosclerosis by inhi-
biting platelet activation, limiting the entry of cells and
lipids into the vessel wall, and maintaining a non-
proliferative and biochemically inactive intima [23].
Endothelial dysfunction
Endothelial dysfunction occurs when there is an imbal-
ance between the vasoconstricting and vasodilating
products (produced directly or indirectly by the endo-
thelium) [24]. Endothelial cell dysfunction can be caused
by multiple factors such as genetics, advance glycation
end products, hyperglycaemia, high blood cholesterol,
hypertension, obesity, diabetes, and smoking [25]. It is
associated with higher aggregation of platelets and
anticoagulant properties; decreased production of NO;
higher secretion of cytokines, chemokines, or adhesion
molecules; and increased reactive oxygen species pro-
duction from the endothelium [26]. Furthermore, indi-
viduals suffering from chronic kidney failure exhibit
endothelial cell dysfunction. There is also a link between
metabolic changes to nitric oxide synthase (NOS) and
chronic kidney disease [27, 28]. NOS is available to
endothelial cells in two types of isoform: inducible and
constitutive or iNOS and cNOS, respectively [29].
Physiological vascular dilation is significantly affected by
the constitutive isoform. In patients with advanced renal
disease, decreased NO production from cNOS has
been observed as a mechanism leading to impaired
endothelium-dependent vasodilation in uraemia [30].
Furthermore, Passauer et al.’s research found a correl-
ation between reduced NO production and reduced
endothelium-based vasodilation in dialysis patients
[31]. The major features of endothelial dysfunction
are recapped in Table 1.
Endothelial dysfunction is also associated with in-
creased oxidative stress and inflammatory changes that
play a role in the development and progression of
atherosclerosis in the early stages, while they increase
the vulnerability of fully developed plaques facilitating
their rupture [32]. There are many techniques used toTable 1 Healthy and dysfunctional endothelium
Healthy endothelium E
Vasodilatory (↑NO, ↑PGI2) I
Decrease oxidative stress, ↓uric acid I
Anticoagulant (↓PAI-1, vWF, P-selectin) P
Rise in endothelial progenitor cells and decrease molecular markers
of damage (circulating endothelial cells, microparticles)
D
o
Anti-inflammatory biomarkers (↓sICAM, sVCAM, E-selectin, CRP,
TNF-alpha, IL-6, MCP-1)
P
I
CRP C-reactive protein, IL-6 interleukin-6, NO nitric oxide, PAI-1 plasminogen activat
sVCAM soluble vascular cell adhesion molecule, TNF-α tumour necrosis factor alpha,assess endothelial function. These techniques can be
either invasive or non-invasive. In invasive techniques,
vasoactive agents are delivered via intra-arterial infusion,
whilst the response is measured with high-resolution
ultrasound or strain gauge plethysmography. In addition,
intravascular infusions of vasoactive stimulants can be
combined with intravascular ultrasound.
Non-invasive techniques includes ultrasound and
magnetic resonance imaging flow-mediated dilatation,
salbutamol-mediated endothelial function measured by
pulse wave analysis or pulse contour analysis, and per-
ipheral arterial tonometry [33, 34]. Ultrasound flow-
mediated dilatation of the brachial artery is the most
widely used in clinical research, and it is currently con-
sidered a standard for a non-invasive assessment of
conduit artery endothelial function [35].
Endothelium dysfunction and AVF maturation
Early fistula failure is usually due to thrombosis which
can be triggered by haematoma, by low flow rates result-
ing from low blood pressure, or by a hypercoagulable
state [36]. On the other hand, progressive neointimal
hyperplasia in the venous outflow system can lead to
stenosis, which can cause late thrombosis of haemodialy-
sis AVF [37, 38]. Arteriovenous fistula anastomoses need
swift proliferation of endothelial cells to restore the bar-
rier, permeability, and biochemical monitoring roles of
endothelial cells in managing vascular repair, local
thrombosis, neointimal hyperplasia, and inflammation
[39]. Because the migration and proliferation of endothe-
lial cells are restricted by uraemia, and because uraemia
causes abnormal vascular remodelling, neointimal hyper-
plasia can sometimes be found at the point of anasto-
mosis of VA [40, 41]. This results in primary access
failure and ineffective dialysis [42]. A recent study sug-
gested that microvascular endothelial function as mea-
sured using peripheral arterial tonometry may be useful
as a predictor of AVF maturation and function [10].
Patients who had impaired flow-mediated dilation (FMD)
with a median value of 5.0% (3–9) did not find any
difference between the patients with successful and/or un-
successful AVF [10]. The finding of impaired endothelialndothelial dysfunction
mpaired vasodilation (↓NO, ↓PGI2)
ncrease oxidative stress (↑ nitrotyrosine and uric acid)
rocoagulant (↑PAI-1, vWF, P-selectin)
ecrement in endothelial progenitor cells and increase molecular markers
f damage (circulating endothelial cells, microparticles)
ro-inflammatory biomarkers (↑sICAM, sVCAM, E-selectin, CRP, TNF-alpha,
L-6, MCP-1)
or inhibitor 1, PGI2 prostacyclin, sICAM soluble intercellular adhesion molecule,
vWF von Willebrand factor
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shown using both venous occlusion plethysmography
techniques [43], and FMD [44]. Owens et al. [45]
determined FMD among 25 CKD patients prior to AVF
creation and found very similar values (5.8 ± 1.0%). Study
explored the correlation between baseline FMD and
subsequent change in the diameter of the artery and vein
at 3 months after AVF creation and found a positive
correlation.
Erdem et al. discovered that during haemodialysis,
turbulent flow, intraluminal pressure, and regular needle
insertion caused endothelial damage, which led to
haemostatic activation in AVF [46]. Wakefield et al.’s
study indicated that thrombus development and blood
clotting could be stimulated by higher levels of factor V,
plasminogen activator inhibitor-1, tissue factor, and von
Willebrand factor, as secreted by a dysfunctional venous
endothelium [47]. Furthermore, a dysfunctional venous
endothelium favours the interactions with circulating
tissue factor-bearing microparticles, further triggering
localized blood clotting activation [48].
Vascular stenosis of arteriovenous fistula is primarily
the result of neointimal hyperplasia [49, 50]. The
pathophysiology of neointimal hyperplasia consists of
the presence of extracellular matrix deposition and pro-
liferation, adherence, and migration of vascular smooth
muscle cell (VSMC), which represents abnormal healing.
Sung et al. [51] found that growth factors and cytokines
act as semi-regulators for the changes to the VSMC re-
sponse. Tumour necrosis factor-α stimulates the synthe-
sis of other pro-inflammatory cytokines and adhesion
molecules; it has a chemotactic activity for monocytes
and stimulates migration and proliferation of VSMC.Fig. 1 Vascular remodelling responsesThe shear stress levels revert back to baseline due to
these vascular reactions (Fig. 1). On the other hand, the
activation of endothelial cells and proliferation, release
of inflammatory and procoagulant substances, and alter-
ations to cellular shape are all events that have been
linked to reduction in shear stress and blood flow. This
manifests as raised levels of neointimal hyperplasia and
vascular constriction [52]. Furthermore, Dardik et al.
[53] has revealed that vascular response seems to be
significantly influenced by the exact type of shear stress.
For instance, matrix metalloproteinase up-regulation,
higher proliferation of cells, and a pro-inflammatory
environment can be caused by oscillatory shear stress
[54]. On the other hand, normal dilatation and
endothelial stability are the outcomes of laminar shear
stress [55].
Corpataux et al. [56] discovered that the fistula vein
instantly deals with huge increase in blood flow follow-
ing the creation of AVF. Additionally, there is an even-
tual thickening of the fistula vein wall and dilation of the
venous lumen. This allows the fistula vein to effectively
deliver sufficient blood for haemodialysis and be regu-
larly needled for dialysis circulation. The next most
significant hemodynamic factor that typically influence
an AV fistula is the circumferential or transmural pres-
sure. Transmural pressure is produced inside the blood
vessel, and previous studies [57, 58] have shown that in-
crease in transmural pressure lead to an activation of
smooth muscle cells, higher levels of extracellular matrix
elements, and raised production of cytokine. These path-
ways invariably lead to the thickening of blood vessel
wall, which result in the reduction of transmural pres-
sure which revert back to basal level.
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that wound healing, migration, proliferation, viability,
and other fundamental endothelial cells biological pro-
cesses are restricted by the uraemic toxins found in the
plasma of individuals with ESRD. This is particularly
true at the site of haemodialysis vascular access. The
failure of these EC processes has played a crucial role in
vascular remodelling. According to Chitalia et al. [61],
vascular remodelling is negatively impacted by EC dys-
function that is caused by uraemia. The result of this is
vascular access failure and can be fatal to patients with
ESRD since it is crucial to achieve vascular access for
haemodialysis.
Certainly, endothelial cell function is also important,
but the most important factor in maturation of AVF
seems to be blood vessel selection and surgical tech-
nique. Blood vessel selection is one the most important
factors in the maturation of AVF. The inadequate vessels
used to construct AVFs have been identified as another
cause of AVF failure. Zadeh et al. [62] conducted a
cross-sectional study using a sample of 96 haemodialysis
patients and found an association between the vein
diameter and the success rate of fistula development. A
vein diameter of <2.5 mm is supposed to be considered
inadequate for formation of an AVF, particularly if mea-
surements remain unchanged following the use of tour-
niquet [63].
Conclusion
The efficiency of haemodialysis treatment relies on a func-
tional status of vascular access. AVF non-maturation is
most commonly characterized by a juxta-anastomotic
stenosis, a histological level such as aggressive neointimal
hyperplasia at the juxta-anastomosis, and an absence of
outward vascular remodelling. Currently, we have rea-
sonable understanding of the mechanisms, pathways,
pathology, and the pathogenesis of venous neointimal
hyperplasia, and vascular stenosis leads to AVF non-
maturation. The combination of advances in cellular and
molecular pathobiology, biomaterials, and drug delivery
techniques has resulted in many innovative therapies
for neointimal hyperplasia. There is a need to identify
the therapies that are best suited for clinical use in
AVF dysfunction.
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